Rejuvenation Technologies Inc.
mRNA therapeutics to extend healthspan entering clinical trials
- Founded
- 2016
- Status
- Active
- Stage
- Early
- Team size
- 2
- Location
- San Francisco, CA, USA
- Category
- Biotech & Drug Discovery
- Sector
- Therapeutics
About Rejuvenation Technologies Inc.
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.
Federal research funding
7 NIH awards totalling $5,965,843, FY2020 to FY2026.
- Advancing a telomere extension biologic to treat alcohol-associated liver damage to IND
- Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic
- TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis
- Clinically-useful vehicles for in vivo delivery of mRNA to stem and progenitor cells
Source: NIH RePORTER.
Company data compiled and maintained by Healthcare Discovery.
